臨床研究等提出・公開システム

The investigation for the usefulness of carnitine medication in patients with decompensated liver cirrhosis (The usefulness of carnitine medication in patients with decompensated liver cirrhosis)

The usefulness of carnitine medication in patients with decompensated liver cirrhosis (The usefulness of carnitine medication in patients with decom pensated liver cirrhosis)

Takaki Akinobu

Okayama University Hospital

2-5-1 Shikata-cho, Kita-ku, Okayama

akitaka@md.okayama-u.ac.jp

Adachi Takuya

Okayama University Hospital

2-5-1 Shikata-cho, Kita-ku, Okayama

+81-86-235-7219

adataku719@yahoo.co.jp

Recruiting

Dec. 25, 2020

Interventional

randomized controlled trial

open(masking not used)

no treatment control/standard of care control

parallel assignment

treatment purpose

The decompensated liver cirrhosis patients with
Child-Pugh score over 7 points, and satisfy the following
criteria.
1. over 20 years old
2. written informed consent
3. can periodically go to hospital

1. already take carinitine
2. The blood concentration of total carinitine and
free carinitine is higher than the normal upper
limit value
3. with a history of any hypersensitivity to ingredients in
L-Cartin FF tablets and Levocarnitine FF tablets.
4. pregnant, unwilling to practice contraception during
the study
5.. lactating female
6. The patient who received other study medicine
or the clinical experimental medicine within three
months before start of this study
7. The investigator judged to be inappropriate as the study
subject

Both

decompensated liver cirrhosis with carnitine deficiency

Intervention group: L-carnitine 1500mg/day medication for 12
weeks. The dose increase and decrease is possible.
non-intervention group: non administration of L-carinitine

the improvement rate of Child-Pugh score

the change of grasping power, serum ammonia,
neuropsychological test,subjective symptom, increase or
decrease medication, safety

+81-86-235-7133

Dec. 14, 2020

No

none